Navigation Links
Neurobiological Technologies Announces Filing of Certificate of Dissolution and Closing of Stock Transfer Books
Date:12/17/2009

EMERYVILLE, Calif., Dec. 17 /PRNewswire/ -- Neurobiological Technologies, Inc. (formerly NTII) ("NTI") announced today that it filed a Certificate of Dissolution with the Secretary of State of the State of Delaware on December 17, 2009. Certificates of Dissolution generally become effective upon filing. The Certificate of Dissolution provides for the dissolution of NTI under the Delaware General Corporation Law. In connection with the filing of its Certificate of Dissolution, NTI also closed its stock transfer books to coincide with the voluntary delisting of its securities from the Nasdaq Capital Market, effective prior to the opening of business on December 17, 2009.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions.

SOURCE Neurobiological Technologies, Inc.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Neurobiological Technologies Announces Extraordinary Dividend of $0.18 per Share
2. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
3. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
4. Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis
5. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
6. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
7. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
8. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
9. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
10. Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics
11. AVAX Technologies, Inc. Closes Bridge Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Dec. 7, 2016  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ... present a company overview at the BMO Capital Markets Prescriptions for ... York, NY . A live webcast of the ... the Ionis website.  The replay will be available within 48 hours ... ...
(Date:12/7/2016)... 7, 2016  Lannett Company, Inc. (NYSE: LCI ) ... Markets 2016 Prescription for Success Healthcare Conference on December 14, 2016 ... New York City . In addition, the ... Guggenheim Securities 4 th Annual Boston Healthcare Conference taking place ... ...
(Date:12/6/2016)...  Alopexx Oncology, LLC announced data from a Phase ... (immunocytokine) composed of interleukin-2 and a CD20-targeting monoclonal antibody. ... cells as Rituxan and maintains the activities of both ... in tumor targeting, engagement of the immune system, and ... the study (abstract #95954) were presented at the 58 ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... ... medicine device WellnessPro Plus for consumers and healthcare professionals to manage chronic ... by expanding the treatment modalities available in a single device. The announcement ...
(Date:12/7/2016)... ... ... “Tomorrow Trump Goes To Washington”: a brief but engaging illustration depicting ... America. “Tomorrow Trump Goes To Washington” is the creation of published author, Nancy Engestrom, ... , Nancy attributes her patriotic nature to her WWII veteran father. She says, ...
(Date:12/7/2016)... ... (PRWEB) December 07, 2016 , ... Angioma Alliance ( http://www.angioma.org ... angiomas, was awarded a grant from the Julian Grace Foundation to increase its ... more people with cavernous angioma than anywhere in the world. Most share a ...
(Date:12/7/2016)... Mateo, CA (PRWEB) , ... December 07, 2016 , ... ... San Francisco Peninsula region, is proud to announce new city-specific pages as part of ... services for the elderly, they often look, first, for local agencies serving their city. ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... collaborate in developing a vaccine against the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). ... available in South Korea for emergency deployment in the event of a future ...
Breaking Medicine News(10 mins):